Clinical Trials Sponsored by Santen Inc.

Total 37545 results

Santen Inc.

Terminated

LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye

Non Infectious Uveitis

United States, India, Italy, Argentina
Santen Inc.

Completed

A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study

Open-angle Glaucoma, Ocular Hypertension

United States, Japan
Santen Inc.

Completed

Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6

Primary Open-angle Glaucoma and Ocular Hypertension

United States
Santen Inc.

Completed

Safety and Efficacy Study of DE-110 Ophthalmic Suspension for the Treatment of Dry Eye Disease

Dry Eye

United States
Santen Inc.

Completed

A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients

Dry Eye Disease

United States
Santen Inc.

Completed

Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-angle Glaucoma

United States
Santen Inc.

Completed

Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

United States
Santen Inc.

Completed

A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study

Glaucoma and Ocular Hypertension

United States
Santen Inc.

Completed

Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects

Age-Related Macular Degeneration

United States, Philippines
Santen Inc.

Completed

A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development Program (SPRING)

Non-Infectious Uveitis of the Posterior Segment of the Eye

United States, France, Turkey, Italy, Austria, India
Santen Inc.

Completed

Study Assessing Double-masked Uveitis Treatment (SAKURA)

Uveitis; Posterior, Disorder

United States, France, Italy, Poland, United Kingdom, Germany, Spain, Austria, Colombia, Israel, India, Turkey, Japan, Peru, Argentina, Brazil, Chile
Santen Inc.

Completed

A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration (VAPOR1)

Age-Related Macular Degeneration

United States
Santen Inc.

Completed

Study Assessing Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients

Dry Eye

United States
Santen Inc.

Completed

DE-117 Spectrum 5 Study

Primary Open-angle Glaucoma and Ocular Hypertension

United States
Santen Inc.

Completed

Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia (OPSIS)

Presbyopia

United States
Santen Inc.

Completed

A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study

Glaucoma and Ocular Hypertension

United States
Santen Inc.

Completed

Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension (ANGEL-2)

Primary Open Angle Glaucoma | Ocular Hypertension

United States
Santen Inc.

Completed

A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration (PAVE)

Age-Related Macular Degeneration

United States
Santen Inc.

Completed

Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SEE-1)

Ocular Hypertension | Open-angle Glaucoma

United States
Santen Inc.

Completed

Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

Open-angle Glaucoma or Ocular Hypertension

United States
Santen Inc.

Completed

A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular Degeneration

Age-Related Macular Degeneration

United States
Santen Inc.

Completed

A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT

Glaucoma and Ocular Hypertension

United States
Santen Inc.

Completed

Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

United States
Santen Inc.

Completed

Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active Comparators

Healthy

United States
Asten Sante

Recruiting

Consequences of Respiratory Devices on Caregivers (CAP2) (CAP2)

Quality of Life

France
Santen Inc.
ActualEyes Inc.

Recruiting

A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD) (PHANTOM)

Fuchs Endothelial Corneal Dystrophy

United States
Santen Inc.
MacuSight, Inc.

Completed

Dose Ranging Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Diabetic Macular Edema

Diabetic Macular Edema

United States
Santen Inc.
MacuSight, Inc.

Completed

Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy

Diabetic Retinopathy | Diabetic Macular Edema

United States
Santen Inc.
MacuSight, Inc.

Completed

A Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injection of Sirolimus in Patients With Dry Eye in the Controlled Adverse Environmental (CAE) Model

Dry Eye

United States
Santen Inc.
MacuSight, Inc.

Terminated

Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration

Age-related Macular Degeneration | Choroidal Neovascularization

United States
Santen Inc.
MacuSight, Inc.

Terminated

Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration (EMERALD)

Age-Related Macular Degeneration | Choroidal Neovascularization

United States
Santen Inc.
Vistakon Pharmaceuticals

Completed

Ocular Tissue Levels of 1.5% Levofloxacin Ophthalmic Solution Compared to an Active Comparator

Cataract

United States
Santen Inc.
Vistakon Pharmaceuticals

Terminated

Ocular Penetration of 1.5% Levofloxacin and 0.5% Moxifloxacin During Corneal Transplant Surgery

Corneal Transplantation

United States
Stanford University
Santen Inc.

Withdrawn

Intravitreal Sirolimus as Therapeutic Approach to Uveitis (SAVE-2)

Panuveitis | Uveitis | Posterior Uveitis | Intermediate Uveitis

United States
The Cleveland Clinic
Santen Inc.

Active, not recruiting

Imaging Quantification of Inflammation (IQI) (IQI)

Uveitis

United States
Santen SAS

Completed

Effect of IKERVIS® Eye Drops Once Daily on the Quality of Vision in Dry Eye Disease Patients With Severe Keratitis (FAST)

Keratitis

France
Santen SAS

Active, not recruiting

A Phase III Multinational Multicenter Investigator-Masked Randomised Active-Controlled Trial Comparing the Efficacy and Safety of DE-130A With Xalatan® in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Surface Disease | Open-Angle Glaucoma or Ocular Hypertension

France
Santen SAS

Completed

Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC)

Conjunctivitis, Vernal

France
Santen SAS

Completed

NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry Eye

Dry Eye

United States
Santen SAS

Completed

Safety and Tolerability of NOVA63035 "Corticosteroid" in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy

Diabetic Macular Edema

United States
Santen SAS

Completed

Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Versus Vehicle in Patients With Moderate to Severe Dry Eye Syndrome

Moderate to Severe Dry Eye Syndrome

France
Asten Sante
Slb Pharma; Withings; Nouvéal

Recruiting

Impact of Patient Involvement in Alerts Management of Telemonitoring CPAP

OSA

France
Lantern Pharma Inc.

Recruiting

Study of LP-184 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

United States
Kangen Pharmaceuticals, Inc

Completed

A Dose Ranging Study Evaluating Efficacy and Safety of NI-03 (Tactic)

Chronic Pancreatitis

United States, Russian Federation, Ukraine
Sentien Biotechnologies, Inc.

Active, not recruiting

A Study of Cell Therapy for Subjects With Acute Kidney Injury Who Are Receiving Continuous Renal Replacement Therapy

Acute Kidney Injury

United States
Hapten Sciences, Inc.

Completed

A Phase I, Single-Center Study of PDC-APB in Healthy Volunteers

Contact Dermatitis

United States
Tanzen Medical Inc

Unknown

The RestEaze Ambulatory Sleep Monitor for Detection of Leg Movements During Sleep in Adults and Children With a Sleep Disturbance

Sleep

United States
Santen SAS

Completed

Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis

Vernal Keratoconjunctivitis

United States, Croatia, France, Germany, Greece, Hungary, India, Israel, Italy, Portugal, Spain
Santen Oy

Completed

A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United Kingdom, United States
Santen SAS

Completed

Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface Disease

Ocular Hypertension | Glaucoma | Ocular Surface Disease

United States

3

Subscribe